Crexendo, Inc.·4

Feb 6, 5:24 PM ET

KORN JEFFREY G 4

4 · Crexendo, Inc. · Filed Feb 6, 2026

Research Summary

AI-generated summary of this filing

Updated

Crexendo (CXDO) CEO Jeffrey G. Korn Receives 10,000 RSU Award

What Happened

  • Jeffrey G. Korn, CEO of Crexendo, was granted 10,000 restricted stock units (RSUs) on February 4, 2026. The RSUs were awarded at $0.00 per unit (no cash paid at grant) and are reported as a derivative award rather than an open‑market purchase or sale.

Key Details

  • Transaction date: 2026-02-04; Form 4 filed: 2026-02-06 (filed within the typical 2‑business‑day window).
  • Grant type/code: A (award/grant) of 10,000 RSUs; reported acquisition price $0.00.
  • Shares owned after transaction: Not reported in the provided Form 4.
  • Footnotes: F1 — each RSU entitles the holder to one share of CXDO common stock upon vesting. F2 — RSUs vest in equal monthly installments over 36 months beginning March 4, 2026, contingent on continued employment; shares will be delivered upon vesting.

Context

  • RSUs are a form of compensation (a derivative award) that convert to actual shares only as they vest; they do not represent immediate share ownership or a market purchase. This grant increases Korn’s potential future stake if he remains employed and the RSUs vest according to the schedule.

Insider Transaction Report

Form 4
Period: 2026-02-04
KORN JEFFREY G
Chief Executive Officer
Transactions
  • Award

    Restricted Stock Units

    [F1][F2]
    2026-02-04+10,00010,000 total
    Exercise: $0.00Common Stock (10,000 underlying)
Footnotes (2)
  • [F1]Each RSU represents the right to receive, upon vesting, one share of CXDO common stock contingent on continued employment.
  • [F2]The RSUs vest in equal monthly installments over 36 months starting on March 4, 2026 until such time as the RSUs are 100% vested, subject to continuous employment. Shares will be delivered upon vesting.
Signature
/s/ Jeffery G. Korn|2026-02-06

Documents

1 file
  • 4
    section16.xmlPrimary

    PRIMARY DOCUMENT